Zobrazeno 1 - 2
of 2
pro vyhledávání: ''
Autor:
Shubham Pant, Samuel McNeely, Ling Gao, Mansoor N. Saleh, Roberto Carlesi, Van K. Morris, C. Terret, Huzhang Mao, Philippe A. Cassier, Amanda Long, Siqing Fu, Lauriane Eberst, Gurudatta Naik, Erin K. Wagner
Publikováno v:
Oncologist
Trial Information Click here to access other published clinical trials. Lessons Learned The combination of the antivascular endothelial growth factor receptor 2 monoclonal antibody, ramucirumab, and the type II MET kinase inhibitor, merestinib, is to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a6da28aca92f18edeb01b84065f999b
https://europepmc.org/articles/PMC7648328/
https://europepmc.org/articles/PMC7648328/
Autor:
Richard Price, Brad Somer, Alan Nicholas, Nicolas Sommer, Howard S. Hochster, James A. Reeves, Johanna C. Bendell, Herbert Hurwitz, Henry Xiong, John F. Palma, John Lee, Benjamin R. Tan, Frank A. Scappaticci, Heinz-Josef Lenz
BACKGROUND. First‐line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5‐fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5‐fluorouracil/leucovorin/irinotecan (FOLFIRI). STEAM (NCT017
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f339bfc70a2024d40c83e1eaadc6da2d
https://europepmc.org/articles/PMC6656450/
https://europepmc.org/articles/PMC6656450/